慢性淋巴细胞白血病的可测量残留病:专家综述与共识推荐
该共识由174名国际多学科专家组成的小组制定,针对慢性淋巴细胞白血病(CLL)可测量残留病(MRD)评估的关键问题提出推荐。推荐涵盖MRD检测方法、样本组织、评估时机与频率、临床应用与试验场景,并提出命名规范,以标准化未来研究的数据采集与解读。
要点
- MRD是CLL治疗期间及结束时高灵敏的疾病负荷指标,与时间事件结局相关。
- 治疗结束时MRD不可测状态在化学免疫治疗中与更优的无进展生存和总生存独立相关。
- 共识推荐涵盖MRD检测方法、组织选择、评估时机与频率及临床应用场景。
核心结论
- MRD评估可作为CLL治疗深度反应的指标,治疗结束MRD不可测状态与化学免疫治疗下更优的PFS和OS独立相关。
- 共识提出MRD检测方法、组织选择、评估时机与频率、临床应用与试验场景及命名规范等推荐,以标准化未来研究。
研究设计与样本
- 国际多学科174人专家组识别CLL MRD关键问题,综述可评估数据并结合当地专家意见形成统一答案与未来研究推荐。
主要发现
- 治疗结束MRD不可测状态在化学免疫治疗下与更优的无进展生存和总生存独立相关。
- MRD状态已成为CLL临床试验的结局焦点。
关键数值与推荐
- 推荐涉及MRD检测方法、检测要求及评估组织、评估时机与频率、临床实践与临床试验中的MRD使用及未来效用,并提出命名规范。
临床怎么用
- 在CLL临床实践中可依据共识推荐规范MRD评估的时机、组织与检测方法,并在临床试验中标准化MRD数据报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Assessment of measurable residual disease (often referred to as "minimal residual disease") has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic lymphocytic leukemia. Undetectable-measurable residual disease status at the end of treatment demonstrated independent prognostic significance in chronic lymphocytic leukemia, correlating with favorable progression-free and overall survival with chemoimmunotherapy. Given its utility in evaluating depth of response, determining measurable residual disease status is now a focus of outcomes in chronic lymphocytic leukemia clinical trials. Increased adoption of measurable residual disease assessment calls for standards for nomenclature and outcomes data reporting. In addition, many basic questions have not been systematically addressed. Here, we present the work of an international, multidisciplinary, 174-member panel convened to identify critical questions on key issues pertaining to measurable residual disease in chronic lymphocytic leukemia, review evaluable data, develop unified answers in conjunction with local expert input, and provide recommendations for future studies. Recommendations are presented regarding methodology for measurable residual disease determination, assay requirements and in which tissue to assess measurable residual disease, timing and frequency of assessment, use of measurable residual disease in clinical practice versus clinical trials, and the future usefulness of measurable residual disease assessment. Nomenclature is also proposed. Adoption of these recommendations will work toward standardizing data acquisition and interpretation in future studies with new treatments with the ultimate objective of improving outcomes and curing chronic lymphocytic leukemia.
引用
- Wierda WG, Rawstron A, Cymbalista F, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021. PMID: 34168283. doi:10.1038/s41375-021-01241-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。